Jefferies & Company Projects Alkermes Sales of $40M - Alkermes (NASDAQ:ALKS)

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Vivitrol drug maker Alkermes, Inc. (NASDAQ: ALKS) announced last night that it received FDA approval for an expanded indication that includes "the prevention of relapse to opioid dependence," Jefferies & Company reports. “We are currently projecting CY11 sales of $40M,” Jefferies & Company writes. “The product has an ~75% gross margin. If one assumes the product was break-even at $25M, then the incremental $11M in gross profit should drop to the bottom line and contribute ~$0.12 to CY11 earnings (assuming no taxes).”Alkermes currently trades for $15.68.

27% profit every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!